Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899704 | 0.82 | GLP1R (0.33) | GLP1R | |
| SCHEMBL21899215 | 0.72 | KDM4E (0.31) | — | |
| SCHEMBL21854428 | 0.71 | ENPP2 (0.32) | — | |
| SCHEMBL22481779 | 0.68 | GLP1R (0.30) | GLP1R | |
| SCHEMBL21919617 | 0.68 | GLP1R (0.35) | GLP1R | |
| SCHEMBL22313517 | 0.68 | — | — | |
| SCHEMBL2737281 | 0.67 | — | — | |
| SCHEMBL21854501 | 0.67 | — | — | |
| SCHEMBL21854473 | 0.67 | — | — | |
| SCHEMBL27276293 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| WO-2020198711-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR USE AS PROTEOLYSIS TARGETING CHIMERA LIGANDS | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198710-A1 | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF | ESSA PHARMA, INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | US | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | GLP1R 1523/4885 |
| US-20200123117-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | GLP1R 1523/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | GLP1R 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.